Cargando…
Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors
Severe acute respiratory syndrome (SARS) led to a life-threatening form of atypical pneumonia in late 2002. Following that, Middle East Respiratory Syndrome (MERS-CoV) has recently emerged, killing about 36% of patients infected globally, mainly in Saudi Arabia and South Korea. Based on a scaffold w...
Autores principales: | Kumar, Vathan, Tan, Kian-Pin, Wang, Ying-Ming, Lin, Sheng-Wei, Liang, Po-Huang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079562/ https://www.ncbi.nlm.nih.gov/pubmed/27240464 http://dx.doi.org/10.1016/j.bmc.2016.05.013 |
Ejemplares similares
-
Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease
por: Ramajayam, R., et al.
Publicado: (2010) -
Inhibitor Recognition Specificity of MERS-CoV Papain-like
Protease May Differ from That of SARS-CoV
por: Lee, Hyun, et al.
Publicado: (2015) -
HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoV
por: Milewska, Aleksandra, et al.
Publicado: (2021) -
Comparative susceptibility of SARS-CoV-2, SARS-CoV, and MERS-CoV across mammals
por: Li, Meng, et al.
Publicado: (2023) -
Human Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 in Children
por: Aleebrahim-Dehkordi, Elahe, et al.
Publicado: (2021)